Bridgewater Associates (Ray Dalio) — VRTX Trade History

Quarter-by-quarter changes in the VERTEX PHARMACEUTICALS INC position · CUSIP 92532F100
Currently held · 1.3 YearsFirst seen: 2017 Q2
QuarterFiledActivitySharesΔ SharesΔ %Value% Port.
2026 Q22026-08-14Reduce10,865-2,492-18.7%$5.4M0.02%
2026 Q12026-05-15Reduce13,357-14,131-51.4%$6.0M0.03%
2025 Q42026-02-13Reduce27,488-10,836-28.3%$12.5M0.04%
2025 Q32025-11-13Add38,3243,934+11.4%$15.0M0.06%
2025 Q22025-08-13New34,39034,390$15.3M0.06%
2025 Q12025-05-14Sold out-710-100.0%
2024 Q42025-02-13Reduce710-2,742-79.4%$285.9K0.00%
2024 Q32024-11-13Reduce3,452-29,777-89.6%$1.6M0.01%
2024 Q22024-08-14Reduce33,229-101,466-75.3%$15.6M0.08%
2024 Q12024-05-14Add134,6952,341+1.8%$56.3M0.28%
2023 Q42024-02-14Reduce132,354-25,995-16.4%$53.9M0.30%
2023 Q32023-11-13Reduce158,349-17,964-10.2%$55.1M0.33%
2023 Q22023-08-11Reduce176,313-27,963-13.7%$62.0M0.38%
2023 Q12023-05-12Add204,276103,457+102.6%$64.4M0.39%
2022 Q42023-02-13Reduce100,819-63,172-38.5%$29.1M0.16%
2022 Q32022-11-10Reduce163,991-53,161-24.5%$47.5M0.24%
2022 Q22022-08-11Add217,152187,000+620.2%$61.2M0.26%
2022 Q12022-05-13Add30,15217,735+142.8%$7.9M0.03%
2021 Q42022-02-14Reduce12,417-2,700-17.9%$2.7M0.02%
2021 Q32021-11-12Reduce15,117-8,139-35.0%$2.7M0.01%
2021 Q22021-08-13Add23,2561,567+7.2%$4.7M0.03%
2021 Q12021-05-14Add21,68918,059+497.5%$4.7M0.04%
2020 Q42021-02-12New3,6303,630$858.0K0.01%
2020 Q32020-11-13
2020 Q22020-08-12
2020 Q12020-05-14
2019 Q42020-02-13Sold out-32,260-100.0%
2019 Q32019-11-13New32,26032,260$5.5M0.05%
2019 Q22019-08-13Sold out-21,889-100.0%
2019 Q12019-05-14New21,88921,889$4.0M0.03%
2018 Q42019-02-13
2018 Q32018-11-13
2018 Q12018-08-13Sold out-15,509-100.0%
2018 Q22018-08-13New15,50915,509$2.6M0.03%
2017 Q42018-02-13
2017 Q32017-11-13Sold out-18,673-100.0%
2017 Q22017-08-10New18,67318,673$2.4M0.02%
2017 Q12017-05-11
2016 Q42017-02-10
2016 Q32016-11-09

Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.